Pharmacology Department, College of Medicine, Minia University, Minya, Egypt.
Immunol Res. 2021 Oct;69(5):457-460. doi: 10.1007/s12026-021-09219-y. Epub 2021 Aug 6.
In this manuscript, COVID-19, Ebola virus disease, Nipah virus infection, SARS, and MERS are suggested to be considered for a novel immunological reclassification as acute onset immune dysrhythmia syndrome (n-AIDS) due to altered monocytic, Th1/Th2, as well as cytokines and chemokines balances. n-AIDs is postulated to be the cause of the acute respiratory distress and multi-inflammatory syndromes which are described with fatal COVID-19, and immunomodulators are suggested to effectively manage the mentioned diseases as well as for other disorders caused by Th1/Th2 imbalance. Meanwhile, para COVID syndrome is suggested to describe various immune-related complications, whether before or after recovery, and to embrace a potential of a latent infection, that might be discovered later, as occurred with Ebola virus disease. Finally, our hypothesis has evolved out of our real-life practice that uses immunomodulatory drugs to manage COVID-19 safely and effectively.
在这篇手稿中,由于单核细胞、Th1/Th2 以及细胞因子和趋化因子平衡的改变,建议将 COVID-19、埃博拉病毒病、尼帕病毒感染、SARS 和 MERS 重新分类为新型免疫失调综合征(n-AIDS)。n-AIDS 被认为是急性呼吸窘迫和多炎症综合征的原因,这些综合征在致命的 COVID-19 中被描述,免疫调节剂被建议有效地治疗上述疾病以及由 Th1/Th2 失衡引起的其他疾病。同时,建议使用“类新冠综合征”来描述各种与免疫相关的并发症,无论是在恢复之前还是之后,并包含一个潜在的潜伏期感染,就像埃博拉病毒病那样,以后可能会发现。最后,我们的假设是基于我们的临床实践,即使用免疫调节剂安全有效地治疗 COVID-19。